Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RWJ-445380 in active rheumatoid arthritis despite methotrexate
2006-003983-73Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RWJ-445380 in rheumatoid arthritis (RA) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: ACR20 response, ACR50 response and 2 more. Started Nov 2006; status: completed.
02
Drugs
RWJ-445380
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-003983-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003983-73.